Cardiovascular disease: risk assessment and reduction, including lipid modification
KEYWORDS: people, cvd, risk, treatment, statin, statins, committee, recommendations, prevention, evidence, cholesterol, recommendation, lipid-lowering, primary, amended

If a person has acute coronary syndrome, do not delay statin treatment. Measure full lipid profile on admission and at 2 to 3 months after starting treatment. [May 2023, amended December 2023] For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on statins for secondary prevention of CVD. Full details of the evidence and the committee's discussion are in evidence review C: statins: efficacy and adverse effects. Treating comorbidities and secondary causes of dyslipidaemia 1.7.6 Treat comorbidities and secondary causes of dyslipidaemia at the same time as starting statin treatment. [December 2023] Optimising statin treatment See the section on optimising statin treatment. Escalating treatment for people on statins 1.7.7 Make decisions about escalating lipid-lowering treatment after an informed discussion between the clinician and the person about the risks and benefits of additional lipid-lowering treatments. [December 2023] 1.7.8 Take into account the person's preferences, the presence of any comorbidities, whether they are on multiple medications, whether they are frail and their life expectancy. (See also NICE's guideline on multimorbidity.) [December 2023] 1.7.9 If the person is taking the maximum tolerated dose and intensity of statin but the
